Testing ARX788 for HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, ARX788, for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It aims to see if this treatment can shrink tumors in patients who have had up to two prior chemotherapy treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your breast cancer must be HER2-positive (a test shows high levels of the HER2 protein).
- The cancer must be advanced, recurrent, or has spread and cannot be removed by surgery.
- You have had no more than 2 prior chemotherapy treatments for this stage of cancer.
- You have at least one tumor that can be measured on scans.
- You are generally well enough to perform daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ARX788, for people with HER2-low breast cancer that has spread or cannot be removed by surgery. The goal is to see if ARX788 helps shrink or control the cancer.
This trial tests a new drug called ARX788 for people with HER2-positive breast cancer that has spread and who have already been treated with T-DXd (trastuzumab deruxtecan). It aims to see if ARX788 can help when other treatments stop working.
This Phase 2 trial studies whether combining pyrotinib with ARX788 given before surgery can work better and be safe in people with HER2-positive breast cancer. It’s designed for tumors that did not respond well enough to earlier trastuzumab and pertuzumab treatment.
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This trial tests a new drug, ATX-898, alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and effective.
Hear when a new HER2-positive Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.